March 20, 2025 07:47 AM EDTUpdated 04:42 PM
R&D

Up­dat­ed: Monte Rosa re­ports first da­ta for mol­e­c­u­lar glue pro­gram li­censed to No­var­tis

Max Gelman

Senior Editor

Monte Rosa Ther­a­peu­tics re­port­ed Phase 1 da­ta Thurs­day morn­ing for a No­var­tis-part­nered pro­gram that the com­pa­nies be­lieve could change the treat­ment par­a­digm for some im­mune …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

No­vo Nordisk says new ear­ly R&D struc­ture will ‘fu­ture-proof’ its busi­ness

Up­dat­ed: FDA ap­proves Al­ny­lam’s Amvut­tra in AT­TR-CM, kick­ing off com­pe­ti­tion with Pfiz­er, Bridge­Bio

Akero ex­ec calls FDA's ac­cel­er­at­ed ap­proval guid­ance for MASH drugs 'bizarre'

CDC vac­cine meet­ing, de­layed ear­li­er this year, is resched­uled

Two-thirds of re­cent rare dis­ease drugs re­lied on just one tri­al, plus con­fir­ma­to­ry ev­i­dence, FDA team finds

Cal­ley Means joins White House as a spe­cial gov­ern­ment em­ploy­ee, will as­sist with MA­HA poli­cies

A service from the Financial Times